Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy profile—VITAL study, GEMCAD 09-02 clinical trial

4034 Background: Standard of care for SCAC has remained unchanged over the past 4 decades. More than 80% of these tumors overexpress the EGFR receptor and